Skip to main content
. 2004 Mar 10;24(10):2535–2541. doi: 10.1523/JNEUROSCI.4456-03.2004

Figure 4.

Figure 4.

Brain sections from a PS1/APPsw transgenic mouse (A, C, D) and a wild-type mouse (B) after intravenous administration of 4 mg/kg BF-168, showing specific binding of BF-168 to amyloid deposits (A, C) and no nonspecific binding in the brain of the wild-type mouse (B). The same brain section from the transgenic mouse was subsequently immunostained with Aβ-specific mAb 6F/3D (D), revealing specific binding of BF-168 to amyloid deposits in vivo. Both compact amyloid deposits (arrows) and diffuse deposits (arrowhead) were labeled with intravenously administered BF-168. Scale bar, 50 μm.